Toxic epidermal necrolysis (TEN) is a severe adverse drug reaction associated with the separation of skin and mucous membranes at the dermal-epidermal junction. Although it is rare, many treatments have been trialed because of its high mortality rate. Active interventions performed to date include the use of systemic corticosteroids, intravenous immunoglobulins (IVIg), cyclosporine, plasmapheresis, antitumor necrosis factor drugs and N-acetylcysteine, but none has been established as the most effective therapy. IVIg and short-term high-dose corticosteroids were regarded as the most promising treatments for TEN in a comprehensive review of all reported TEN cases from 1975 2003. When used with an appropriate dose and timing, the beneficial effects of IVIg can be maximized. Although no randomized controlled trials have been conducted, cyclosporine and plasmapheresis are considered to be beneficial.
Introduction
Toxic epidermal necrolysis (TEN) is a severe adverse drug reaction associated with the separation of skin and mucous membranes at the dermal-epidermal junction 1 .
Although it is rare, many treatments have been trialed because of its high mortality rate. Active interventions performed to date include the use of systemic corticosteroids, intravenous immunoglobulins (IVIg), cyclosporine, plasmapheresis, anti-tumor necrosis factor drugs and Nacetylcysteine, but none has been established as the most effective therapy 2 .
The evidence for each of these treatments will be reviewed and evaluated in this paper.
Systemic Corticosteroids
Systematic corticosteroids, first reported in 1976, have been the lonest used treatment for TEN. The therapeutic effects on TEN are inconclusive ( Table 1 ) 3 8 . There have been no randomized controlled trials to determine their effects, but overall, their use has declined primarily due to concern about detrimental side effects, and the in- patients treated only with supportive care were compared. The former group had a survival rate of 33%, whereas the latter had a survival rate of 66%. The latter group also had a lower incidence of gastrointestinal ulcers and candida sepsis 4 . Thus, from this study, the association between systemic corticosteroid use and the increased risk of gastrointestinal problems and infection emerged. This use also led to increased mortality, prompting the author of this study to suggest that the use of steroids for the treatment of TEN should be contraindicated 9, 10 . IVIg may have contributed to this decline because it was reported relatively soon thereafter, in 1998, to have a plausible mechanism for the treatment of TEN 11 . Indeed, in a systematic review of the treatment efficacy for TEN patients in burn centers, until 2011, the number of patients treated with corticosteroids was 30%, 33 .3% in the latter group. The latter group, with better mortality, had more patients on corticosteroids and shortterm therapy. Despite that, the difference in the actual mortality rates between the two groups showed no statistical significance 8 .
Intravenous Immunoglobulins
IVIg became a popular choice for treatment for TEN in 1998 ( Table 2) 11, 13 22 . The proposed mechanism of action of IVIg was that it contained anti-Fas antibodies that inhibited the Fas/Fas ligand (FasL) interaction, preventing further apoptosis of keratinocytes, and arresting the progression of TEN. Ten TEN patients were enrolled in an IVIg, each study with more than 9 TEN patients enrolled.
Six studies suggested the effectiveness of IVIg, and 5 of the 6 used an IVIg dose of more than 2 g/kg. Patients who received total doses of 2 g/kg or more had a 59% reduction when the mortality predicted by SCORTEN was compared with the actual mortality rate. The predicted mortality was 34±4%, and the actual mortality rate was 14±8%. Patients who received less than 2 g/kg had a 3% reduction of the predicted, which was 31±7%, while the actual mortality rate was 30±19%. Because this was a literature review, there was no unified treatment regimen with variable doses and durations, or unified diagnosis, making the results less reliable 15 . In addition to the dose, the timing of administration may affect mortality. single-center studies presumably treating the patients without differences, allowing the effectiveness of IVIg to be analyzed 17, 20 . In a study in 2012, all the patients received 4 g/kg IVIg within 72 hours after admission to a burn unit, over a 3 day period, but there was no improvement in survival. Of the 82 TEN patients, 24 died and the observed mortality rate was 29%. The mortality predicted by SCORTEN was 26% (22 patients), and there was no significant difference between the two (p=0.61).
Age could have made the risk of mortality higher, because the mean age of the patients was 45.1 years, and it was reported in one study that age greater than 40 years had an OR of 4.57 (95% CI 1.58 13.2) for mortality 17 . In a study in 2013, 64 SJS/TEN patients were given a mean dose of 2 4 g/kg IVIg. The mortality rates of the patients who received a high dose (! 3 g/kg/day) and those receiving a low dose (<3 g/kg/day) did not significantly differ, with the observed mortality being 31% (n=13) for the high-dose group, and 26% (5) for the low-dose group (p=0.71). More than half of the patients were Chinese, and the mean age was 57 years old. Such factors could have affected the results 20 . What can be said for both the studies discussed above is that, considering the incidence rate of TEN reported throughout the world, the number of patients reported seems very high. It could be that the oids varied, the number of TEN patients seemed to be more than the reported incidence rates, and there were more SCORTEN 1 and 2 patients than those with scores of 3 or more, which could have affected the results 19 .
Cyclosporine
Cyclosporine inhibits the activation of CD4+ and CD8+ T cells, and the subsequent release of granulysin, granzyme and perforin. Nuclear factor-κB (NF-κB) is thereby inhibited, working against apoptosis. Although there have been no randomized controlled trials done, cyclosporine tends to be beneficial for the treatment of TEN (Table   3 ) 24 27 . The doses (3 10 mg/kg/day) and durations vary but have been reported to arrest the disease progression and promote re-epithelialization 9, 12 . A limitation in the active use for the treatment of TEN is that the full therapeutic effect takes more than 1 month. There are also concerns over the renal and hepatic toxicity of cy- , which might have influenced the results. Cyclosporine is suggested to be more effective for the The number of sessions varies and both PE and DFPP 40 2012 Case series NAC 300 mg/kg Effective Paquet et al. 41 2014 Case series NAC 150 mg/kg ±infliximab 5 mg/kg Ineffective Yavuz et al. 42 2014 Case report IVIg 0.4 g/kg ×5 days+NAC 300 mg/kg ×1+150 mg/kg ×1 Effective TEN, toxic epidermal necrolysis; NAC, N-acetylcysteine are used. In the future, it will be important to determine the most effective treatment regimen to avoid confusion.
Anti-TNF Therapy
TNF-α increases in TEN and, although the exact mechanism is unknown, it is generally acknowledged it largely contributes to the pathogenesis of TEN (Table 5 ) 35 38 . As treatments for TEN were sought, the effect of thalidomide, an inhibitor of TNF, was evaluated in a doubleblind randomized placebo controlled study 35 . A total of 22 patients were in the trial, with 12 actually treated and 10 receiving a placebo. Treated patients were given 200 mg of thalidomide twice daily for 5 days. The primary endpoint was the measurement of the progression of skin detachment after seven days, but the trial was terminated due to a high mortality rate. Those who were being treated had a mortality rate of 83% compared to 30% in the placebo group (relative risk 2.78, 95% CI 1.04 7.40).
The overall mortality was thus 59% higher than the 
N-acetylcysteine
N-acetylcysteine (NAC), a precursor of glutathione, has been used because an increase of glutathione enhances the detoxification of drugs (Table 6 ) 39 42 . It has been used orally for pulmonary disorders as an expectorant and intravenously for acetaminophen overdose. NAC 300 mg/ kg was given intravenously, and had positive results 9, 12, 39, 40 . In a recent case report, a child with TEN who was unresponsive to a steroid and IVIg was treated with NAC 42 . NAC is a non-toxic drug, inexpensive and quite safe, with a long half-life of 1 2 days in patients with normal liver function 39, 42 , and probably still works after cessation of the drug 39 . It acts to inhibit the production of cytokines, TNF-α, and IL1, and expression of skin homing receptor cutaneous lymphocyte associated antigen, working to suppress apoptosis 42 . However, in another recent study in 2014, NAC treatment did not reverse the evolving TEN process. Ten patients were given NAC 150 mg/kg alone or in combination with the anti-TNF-α antibody infliximab. The mean mortality rate with only NAC was 20%, and with the combination it was 40%. The predicted SCORTEN mortality rates were 20.4% in the former group and 21.4% in the latter 41 . The actual mortality rate with only NAC had no significant decrease compared to the predicted mortality. The actual mortality with the combination was higher than predicted, which could have been due to the combination with infliximab.
Although NAC is thought to inhibit TNF-α, it is possible that together with infliximab the anti-TNF effect weakened.
Conclusion
As no gold standard for the active intervention for TEN has been established, the choice of treatment relies partly on the available guidelines and the experience of the dermatologist. There is still much to be investigated regarding the pathogenesis of TEN, and new findings may contribute to the identification of an effective active intervention strategy 43 . Although difficult to perform, randomized controlled trials for available active interventions should be performed to better clarify their potential efficacy.
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